Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes. This long-acting analog shares 94% sequence homology with human GLP-1 and exhibits prolonged action through albumin binding.
The mechanism of action involves glucose-dependent stimulation of insulin secretion while simultaneously suppressing glucagon secretion. Clinical studies demonstrate significant improvements in glycemic control and potential benefits for weight management.
Our facility produces pharmaceutical-grade Semaglutide under strict GMP conditions. The product undergoes comprehensive analytical testing including HPLC, MS, and amino acid analysis to ensure quality and purity standards.
Key research applications include:
- Metabolic disorder studies
- Glucose homeostasis research
- Obesity-related investigations
- Cardiovascular protection studies
Note: This product is intended for research purposes only. Not for human consumption or diagnostic use. Proper laboratory handling procedures should be followed at all times.